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geted agents. However, breast cancer awareness, screening, current 
therapy strategies, availability of molecular typing as well as access 
to new treatment options differ substantially between different na-
tions. We are convinced that it is therefore also our responsibility 
to ensure that patients in other parts of the world are not being left 
behind. At present, even simple steps would help a lot: for example, 
quality assured routine estrogen receptor determination and adju-
vant tamoxifen therapy (monthly costs: 9 €) which is not routine in 
many countries, may reduce long-term mortality by 1/3.
Fortunately, current international guidelines, such as the St. 
Gallen conference for early breast cancer [5, 6] or even more so 
ABC in Lisbon for the advanced setting [7, 8], are already consider-
ing these international differences by proposing so-called ‘minimal 
standards of care’ that can be followed worldwide. Moreover, new 
criteria and scales for evaluating and scoring the added value of 
new drugs published by the American Society of Clinical Oncology 
(ASCO) [9] and the European Society for Medical Oncology 
(ESMO) [10], aim to assess new drugs on a global level for their 
true added benefit compared to current standards of care. These 
frameworks aim to provide objective criteria beyond national 
boundaries and may thus indeed be helpful to ensure access to 
truly innovative compounds in countries with limited resources. 
In short: breast cancer will remain a global problem and it is our 
responsibility to support global solutions that will benefit patients 
worldwide.
Breast cancer is a global problem. In 2012, more than 1.5 million 
women were newly diagnosed with this disease worldwide, and about 
half a million women died from the disease (www.globocan.iarc.fr). 
Incidence and mortality rates differ greatly between countries and 
world regions. Whereas incidence as well as mortality tend to de-
crease in several European countries or Canada, both are still rising 
in some South American countries [1] and other parts of the world. 
The CONCORD 2 survey included more than 5.5 million women 
from about 200 registries in more than 50 countries for the recent 
report in 2015. For women diagnosed between 2005 and 2009, the 
5-year survival was 80% or more in 34 countries around the globe. 
Yet, in some countries 5-year survival still was substantially lower, in 
particular in India, some Asian countries or in South Africa [2].
We as the editors-in-chief have therefore invited several inter-
national colleagues to write about breast cancer incidence and 
mortality in their region of the world for this last issue of Breast 
Care in the year 2015. Fan and colleagues [3] discuss the situation 
in Asia while E. Kantelhardt and her colleagues [4] focus on breast 
cancer in Africa. Both regional situations are not widely known in 
European countries, and thus these reports may help to further our 
understanding for breast cancer as a global problem. 
Our current scientific and clinical approach of breast cancer in 
the Western world is based on subgrouping the disease into more 
and more refined molecular subgroups that subsequently are to be 
treated according to their tumor biology with newly developed tar-
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